A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESTORE
- 05 Dec 2011 Planned number of patients changed from 72 to 80 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Planned end Ddte changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.